Abstract
Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.
Original language | English (US) |
---|---|
Pages (from-to) | 935-950 |
Number of pages | 16 |
Journal | Future oncology (London, England) |
Volume | 20 |
Issue number | 14 |
DOIs | |
State | Published - May 1 2024 |
Keywords
- effectiveness
- IRd
- ixazomib
- ixazomib-lenalidomide-dexamethasone
- multiple myeloma
- pooled analysis
- progression-free survival
- proteasome inhibitor
- relapsed/refractory
- routine clinical practice
- time-to-next treatment
ASJC Scopus subject areas
- Oncology
- Cancer Research